SGEN Stock - Seattle Genetics Inc.

SGEN Stock Chart

SGEN Profile

Seagen Inc., a leading biotechnology firm, focuses on the development and global commercialization of innovative cancer therapies. Based in Bothell, Washington, the company is dedicated to advancing treatments that target various forms of cancer, both in the United States and internationally. Seagen's flagship products include ADCETRIS, an antibody-drug conjugate (ADC) designed for Hodgkin lymphoma and CD30-positive T-cell lymphomas, and PADCEV, an ADC targeting Nectin-4 for advanced urothelial cancer.

In addition to these therapies, Seagen offers TUKYSA, an oral small molecule inhibitor specifically for HER2-positive breast cancer. The company continues to expand its pipeline with promising candidates like TIVDAK for metastatic cervical cancer, Ladiratuzumab Vedotin for metastatic breast cancer, Disitamab Vedotin, a novel ADC targeting HER2, and several other compounds targeting various cancer diseases such as SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70.

Seagen collaborates with prominent entities in the pharmaceutical and biotechnology sectors, including Takeda Pharmaceutical Company Limited, Agensys, Inc., Genmab A/S, Merck, and RemeGen Co. Ltd. These partnerships underscore Seagen's commitment to advancing cancer treatment through collaborative research and development efforts.

Originally founded as Seattle Genetics, Inc. in 1997 and rebranded as Seagen Inc. in October 2020, the company has established itself as a leader in the oncology space. With a robust portfolio of therapeutic innovations and a strong emphasis on scientific research, Seagen continues to drive forward in its mission to improve outcomes for cancer patients worldwide.

SGEN Revenue Chart

SGEN Earnings

Analyst Ratings